PROCEPT BioRobotics Corp (NAS:PRCT)

$ 62 -0.04 (-0.06%) Market Cap: 3.19 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 12.07 GF Score: 40/100

Q1 2024 Procept Biorobotics Corp Earnings Call Transcript
May 01, 2024

$60.61 (+14.40%)

Earnings
Q4 2023 Procept Biorobotics Corp Earnings Call Transcript
Feb 27, 2024

$50.75 (+3.91%)

Earnings
Q3 2023 PROCEPT BioRobotics Corp Earnings Call Transcript
Nov 01, 2023

$27.55 (+2.84%)

Earnings
Q2 2023 PROCEPT BioRobotics Corp Earnings Call Transcript
Jul 27, 2023

$35.14 (-7.14%)

Earnings
PROCEPT BioRobotics Corp at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 PROCEPT BioRobotics Corp Earnings Call Transcript
Apr 27, 2023

$26.7 (-25.31%)

Earnings
Q4 2022 PROCEPT BioRobotics Corp Earnings Call Transcript
Feb 28, 2023

$37.45 (+0.24%)

Earnings
PROCEPT BioRobotics Corp at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Procept Biorobotics Corp Earnings Call Transcript
Nov 03, 2022

$44 (-0.48%)

Earnings
Q2 2022 Procept Biorobotics Corp Earnings Call Transcript
Aug 04, 2022

$38.37 (-4.77%)

Earnings
Procept Biorobotics Corp At The American Urology Association Annual Meeting Call Transcript
May 13, 2022
Procept Biorobotics Corp at Bank of America Healthcare Conference Transcript
May 11, 2022
Q1 2022 Procept Biorobotics Corp Earnings Call Transcript
May 05, 2022

$35.13 (-5.59%)

Earnings
Q4 2021 Procept Biorobotics Corp Earnings Call Transcript
Mar 08, 2022

$24.99 (+6.20%)

Earnings
Q3 2021 Procept Biorobotics Corp Earnings Call Transcript
Nov 04, 2021

$43.97 (-2.25%)

Earnings

Procept Biorobotics Corp At The American Urology Association Annual Meeting Call Transcript

May 13, 2022 / 01:30PM GMT

Release Date Price: $35.64 (+11.41%)

Transcript 10-Q

Reza Zadno

PROCEPT BioRobotics Corporation - President, CEO & Director

We can start. Good morning, everyone. Sorry, there were some delays for Internet. Welcome to PROCEPT investor event. We are thrilled to have this meeting here during AUA in New Orleans. It's great to see everyone, and those of you on Zoom or phone. Thanks for joining us, and I hope you can hear me well.

Please review our safe harbor statement. My name is Reza Zadno. I'm President and CEO at PROCEPT. Today with me, we have Kevin Waters, our Chief Financial Officer; Sham Shiblaq, our Chief Commercial Officer; and Barry Templin, our Senior Vice President of Clinical and Medical Affairs. Sham will introduce the surgeons, who will speak later. The agenda for today is the management team will make an introduction to the company on the clinical, financial and commercial strategy and then physicians will talk about their experience with our population, and there will be time for Q&A at the end. So please hold your questions for the end of the meeting.

BPH is the #1 reason men see a urologist. About 50% of men

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.